For further information contact:
Investor & Media Relations Ian Stone Robert Flamm, Ph.D. Russo Partners LLC Russo Partners LLC Tel: (619) 528-2220 Tel: (212) 845-4226 Fax: (619) 528-2297 Email: email@example.com Email: firstname.lastname@example.org www.russopartnersllc.com
The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements and information regarding the registration of Helix's common shares with the U.S. Securities & Exchange Commission and Helix's business, which statements and information can be identified by the use of forward-looking terminology such as "believe," "look," "next", "will," "future", "anticipation", "plan", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: uncertainty whether Helix's shares will be actively solicited and traded by licensed brokers in the U.S. or that Helix's liquidity and U.S. investor ba
|SOURCE Helix BioPharma Corp.|
Copyright©2009 PR Newswire.
All rights reserved